Infants and children who are given prescription acid-reducing medications face a substantially higher risk of developing Clostridium difficile infection, a potentially severe colonic disorder. The findings, reported by Columbia University Medical Center (CUMC) researchers, suggest that pediatricians may do more harm than good by prescribing these drugs for children who have non-specific gastrointestinal symptoms such as occasional vomiting. The study was published recently in the online edition of Clinical Infectious Diseases.
“There’s no question that acid-reducing medications alleviate heartburn in adults, but there’s little evidence of benefit in healthy infants and younger children,” said lead author Daniel E. Freedberg, MD, MS, assistant professor of medicine at CUMC. “Given our findings about the risk involved, pediatricians may hesitate before prescribing these drugs unless there is evidence of acid-related disease.”
The rate of Clostridium difficile, often called C. diff., infection in children is increasing, with a ten-fold rise from 1991 to 2009. For unknown reasons, the infection has recently emerged as a problem in relatively healthy children lacking traditional risk factors.
C. diff. is a bacterium that can cause severe, even fatal, colonic inflammation. The most important risk factor for C. diff. infection is exposure to antibiotics. Antibiotics are thought to disturb the healthy balance of microbes in the intestinal tract, allowing C. diff. to flourish. Other risk factors for infection are inflammatory bowel disease, immune system compromise, advanced age, and hospitalization (since the bacterium is common in health-care settings).
Studies have shown that use of medications called proton pump inhibitors (PPIs) may contribute to C. diff. infection in adults. “The use of PPIs in the pediatric population is rising rapidly, which is why we felt it was important to find out if these medications are associated with an increased risk of C. diff. in children,” said senior author Julian A. Abrams, MD, MS, Florence Irving Assistant Professor of Medicine at CUMC.
The study examined whether use of PPIs and another type of common acid-reducing medication—histamine-2 receptor antagonists (H2RAs)—might be contributing to the increased incidence of C. diff infection in children who have no known risk factors. “Previous studies have looked at the effects of these drugs on children with chronic illnesses that make them prone to C. diff. Less attention has been paid to relatively healthy children, including ‘happy spitters’ or infants who occasionally regurgitate but probably don’t have anything truly wrong with them,” said Dr. Freedberg.
The researchers examined the health records of children in The Health Improvement Network, a database of electronic medical records maintained by general practitioners throughout the United Kingdom, using data collected from 1995 to 2014. (Children with chronic conditions that might be associated with C. diff. infection were excluded.) The study identified 650 outpatients who had been diagnosed with C. diff. infection. Each patient’s recent use of PPIs/H2RAs was compared with that of five age- and sex-matched controls who did not have C. diff infection.
The study found that 2.6% (17 of 650) of the children diagnosed with C. diff. infection had used
PPIs/H2RAs within 90 days, compared with just 0.3% (8 of 3,200) of the controls. In other words, use of acid-reducing drugs resulted in a seven-fold increase in risk for infection with C. diff. The effect was stronger for PPIs, which are more powerful than H2RAs.
The researchers suspect that, like antibiotics, acid reducing medications may increase the risk of C. diff. infection by altering the gastrointestinal microbiome.
“The microbiome in children is highly mutable up until age four or five,” said Dr. Freedberg. “It is unknown whether changes during that formative period, due to antibiotics or PPIs, could alter the microbiome’s ultimate trajectory.”
The paper is titled, “Use of Acid Suppression Medication is Associated with Risk for C. difficile Infection in Infants and Children: A Population-Based Study.” The senior author of the study is Julian A. Abrams, MD, MS, Florence Irving Assistant Professor of Medicine at CUMC. The other contributors are: Esi S. Lamousé-Smith (CUMC), Jenifer R. Lightdale (UMass Memorial Children’s Medical Center, Worcester, MA), Zhezhen Jin (CUMC), and Yu-Xiao Yang (University of Pennsylvania, Philadelphia, PA).
The study was funded by a Clinical Research Award from the American College of Gastroenterology, a mentored career development award through the National Center for Advancing Translational Sciences’ Clinical and Translational Science Awards program (KL2 TR000081), and the Harold Amos Faculty Development Award from the Robert Wood Johnson Foundation.
The authors declare no financial or other conflicts of interest.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.